Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2026, detailing the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. The report confirms the election of Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, shareholders provided advisory approval for executive compensation. Key outcomes include the successful election of all nominated directors, indicating strong shareholder confidence in the current board's leadership. The ratification of the auditor received substantial support, reinforcing the company's commitment to financial transparency and robust auditing practices. The advisory vote on executive compensation also passed with a significant majority, suggesting shareholder alignment with the company's compensation philosophy for its named executive officers.
Key Highlights
- 1All nominated Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders.
- 2PricewaterhouseCoopers LLP was ratified as Regeneron's independent registered public accounting firm for the fiscal year ending December 31, 2026, with strong shareholder approval.
- 3Shareholders approved, on an advisory basis, the compensation of the Company's named executive officers.
- 4The election of directors saw significant 'For' votes, with Dr. Huda Y. Zoghbi and Dr. David P. Schenkein receiving over 100 million and 99 million 'For' votes, respectively.
- 5The ratification of the independent auditor received overwhelming support, with approximately 93% of the cast votes in favor.
- 6The advisory vote on executive compensation also garnered substantial shareholder support, with over 90% of the cast votes in favor.